Clinical trial
Radiographic and Clinical Outcomes of Stress Endplate Augmentation in Patients With Low Bone Mass Undergoing Oblique Lumbar Interbody Fusion for Degenerative Lumbar Disease: A Prospective Observational Cohort Study
NCT07891663 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Radiographic and Clinical Outcomes of Stress Endplate Augmentation in Patients With Low Bone Mass Undergoing Oblique Lumbar Interbody Fusion for Degenerative Lumbar Disease: A Prospective Observational Cohort Study
- Lead sponsor
- Xuanwu Hospital, Beijing
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 1, 2029
- Enrollment
- 300 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
degenerative lumbar disease
Arms
As registered; 2 arms.
-
OLIF With Stress Endplate Augmentation
Patients with low bone mass and degenerative lumbar disease undergoing oblique lumbar interbody fusion (OLIF) with stress endplate augmentation of the vertebral bone adjacent to the endplates supporting the interbody cage.
-
OLIF Without Stress Endplate Augmentation
Patients with low bone mass and degenerative lumbar disease undergoing OLIF without stress endplate augmentation.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Cage Subsidence at 18 Months After Surgery
Number of participants with interbody cage subsidence, defined as a decrease of more than 2 mm in intervertebral disc height at any operated level compared with the postoperative predischarge imaging reference. A participant with subsidence at one or more operated levels is counted once. Participants undergoing revision surgery for cage subsidence before the 18-month assessment are also counted as having the outcome.
Lead sponsor's other trials
Xuanwu Hospital, Beijing, most recent start first.
+358 more trials See the organization page